Answers are grounded in this paper and cite their sources.
We isolated a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2 variant from a person with coronavirus disease 2019 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither nirmatrelvir resistance nor absence of neutralizing immunity was a likely cause of the recrudescence.
No takes yet. Share an insight, caveat, or question.
Carlin et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: